Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.38 |
| ▸ | HTR2C | P28335 | 7/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.33 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 5/20 | 0.32 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25818065 | 0.82 | HTR2C (0.57) | HTR2AHTR2CCYP1A2HTR2B | |
| SCHEMBL25301751 | 0.82 | HTR2C (0.43) | HTR2AHTR2CCYP1A2GLO1 | |
| SCHEMBL30404244 | 0.82 | HTR2C (0.43) | HTR2AHTR2CCYP1A2GLO1 | |
| SCHEMBL24110220 | 0.82 | HTR2C (0.43) | HTR2AHTR2CCYP1A2GLO1 | |
| SCHEMBL25818067 | 0.80 | HTR2A (0.38) | HTR2AHTR2CCCR1CCR5CCR8 | |
| SCHEMBL25299990 | 0.78 | MKNK2 (0.36) | HTR2AHTR2CCYP1A2HTR2B | |
| SCHEMBL30404154 | 0.78 | MKNK2 (0.36) | HTR2AHTR2CCYP1A2HTR2B | |
| SCHEMBL24110362 | 0.78 | MKNK2 (0.36) | HTR2AHTR2CCYP1A2HTR2B | |
| SCHEMBL21704227 | 0.77 | CCR1 (0.42) | HTR2AHTR2CCCR1CCR5CCR8 | |
| SCHEMBL24109812 | 0.77 | HTR2C (0.47) | HTR2AHTR2CCCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | GAP43, SLC18A2, PNMT | HTR2A 10/4885HTR2C 35/4885CCR1 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.